

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	EMVision Medical Devices Ltd
<b>ABN</b>	38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mr John Keep
<b>Date of last notice</b>	22 December 2021

#### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	JOHN KEEP & SONS PTY LTD – Controller of company  GLENSBURG PTY LTD <TYTO CORPORATION PENSION FUND A/C> - Controller of trustee and beneficiary of trust
<b>Date of change</b>	1 December 2022
<b>No. of securities held prior to change</b>	JOHN KEEP & SONS PTY LTD 607,500 ordinary shares (EMV)  GLENSBURG PTY LTD <TYTO CORPORATION PENSION FUND A/C> 1,100,000 ordinary shares (EMV)  JOHN KEEP 347,170 ordinary shares (EMV)
<b>Class</b>	Unlisted options
<b>Number acquired</b>	300,000

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$130,008 option value as per assumptions outlined in AGM Notice of Meeting
<b>No. of securities held after change</b>	JOHN KEEP & SONS PTY LTD 607,500 ordinary shares (EMV)  GLENSBURG PTY LTD <TYTO CORPORATION PENSION FUND A/C> 1,100,000 ordinary shares (EMV) 300,000 unlisted options, exercise price \$2.25, expiry date 31 Dec 2025  JOHN KEEP 347,170 ordinary shares (EMV)
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of unlisted options following approval at Annual General Meeting.

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	EMvision Medical Devices Ltd
<b>ABN</b>	38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mr Tony Keane
<b>Date of last notice</b>	22 December 2021

#### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	PATRICIA KERRY KEANE & ANTHONY GERARD KEANE <THE KEANE FAMILY A/C> - Trustee and beneficiary of trust
<b>Date of change</b>	1 December 2022
<b>No. of securities held prior to change</b>	MR ANTHONY GERARD KEANE 100,000 ordinary shares (EMV)  PATRICIA KERRY KEANE & ANTHONY GERARD KEANE <THE KEANE FAMILY A/C> 500,000 ordinary shares (EMV)
<b>Class</b>	Unlisted options
<b>Number acquired</b>	200,000
<b>Number disposed</b>	Nil

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$86,672 option value as per assumptions outlined in AGM Notice of Meeting
<b>No. of securities held after change</b>	MR ANTHONY GERARD KEANE 100,000 ordinary shares (EMV)  PATRICIA KERRY KEANE & ANTHONY GERARD KEANE <THE KEANE FAMILY A/C> 500,000 ordinary shares (EMV) 200,000 unlisted options, exercise price \$2.25, expiry date 31 Dec 2025
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of unlisted options following approval at Annual General Meeting.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	EMVision Medical Devices Ltd
<b>ABN</b>	38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mr Geoff Pocock
<b>Date of last notice</b>	22 December 2021

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	OOFY PROSSER PTY LTD <DRONES FAMILY A/C> - Controller of trustee and beneficiary of trust
<b>Date of change</b>	1 December 2022
<b>No. of securities held prior to change</b>	OOFY PROSSER PTY LTD <DRONES FAMILY A/C> 855,000 ordinary shares (EMV)
<b>Class</b>	Unlisted options
<b>Number acquired</b>	200,000
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$86,672 option value as per assumptions outlined in AGM Notice of Meeting

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	OOFY PROSSER PTY LTD <DRONES FAMILY A/C> 855,000 ordinary shares (EMV) 200,000 unlisted options, exercise price \$2.25, expiry date 31 Dec 2025
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of unlisted options following approval at Annual General Meeting.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	EMvision Medical Devices Ltd
<b>ABN</b>	38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Philip Dubois
<b>Date of last notice</b>	7 December 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	BONATA PTY LTD <AZTEC INVESTMENT A/C> - Controller of trustee and beneficiary of trust  ALPHA SUPER PTY LTD <DUBOIS SUPERANNATION A/C> - Controller of trustee and beneficiary of super fund
<b>Date of change</b>	1 December 2022
<b>No. of securities held prior to change</b>	BONATA PTY LTD <AZTEC INVESTMENT A/C> 7,500 ordinary shares (EMV)  ALPHA SUPER PTY LTD <DUBOIS SUPERANNATION A/C> 40,000 ordinary shares (EMV) 500,000 unlisted options, exercise price \$3.95, expiry date 29 September 2023
<b>Class</b>	Unlisted options

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number acquired</b>	200,000
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$86,672 option value as per assumptions outlined in AGM Notice of Meeting
<b>No. of securities held after change</b>	BONATA PTY LTD <AZTEC INVESTMENT A/C> 7,500 ordinary shares (EMV)  ALPHA SUPER PTY LTD <DUBOIS SUPERANNATION A/C> 40,000 ordinary shares (EMV) 500,000 unlisted options, exercise price \$3.95, expiry date 29 Sep 2023 200,000 unlisted options, exercise price \$2.25, expiry date 31 Dec 2025
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of unlisted options following approval at Annual General Meeting.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	EMVision Medical Devices Ltd
<b>ABN</b>	38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Ronald Weinberger
<b>Date of last notice</b>	22 December 2021

#### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Deborah Joan Weinberger (spouse)
<b>Date of change</b>	1 December 2022
<b>No. of securities held prior to change</b>	Dr Ronald Peter Weinberger: 1,885,125 fully paid ordinary shares 1,000,000 unlisted options, exercise price \$1.25, expiry date 6 May 2023  Deborah Joan Weinberger: 20,000 fully paid ordinary shares
<b>Class</b>	Unlisted options
<b>Number acquired</b>	500,000
<b>Number disposed</b>	Nil

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$216,679 option value as per assumptions outlined in AGM Notice of Meeting
<b>No. of securities held after change</b>	Dr Ronald Peter Weinberger: 1,885,125 fully paid ordinary shares 1,000,000 unlisted options, exercise price \$1.25, expiry date 6 May 2023 500,000 unlisted options, exercise price \$2.25, expiry date 31 Dec 2025  Deborah Joan Weinberger: 20,000 fully paid ordinary shares
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of unlisted options following approval at Annual General Meeting.

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	EMvision Medical Devices Ltd
<b>ABN</b>	38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mr Scott Kirkland
<b>Date of last notice</b>	22 December 2021

#### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	KIRKLAND CAPITAL PTY LTD <THRILL FURKHAND A/C> - Controller of Trustee and beneficiary of trust
<b>Date of change</b>	1 December 2022
<b>No. of securities held prior to change</b>	Mr Scott Philip Kirkland 3,854,155 ordinary shares (EMV)  KIRKLAND CAPITAL PTY LTD <THRILL FURKHAND A/C> 415,000 total ordinary shares (EMV)
<b>Class</b>	Unlisted options
<b>Number acquired</b>	500,000
<b>Number disposed</b>	Nil

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$216,679 option value as per assumptions outlined in AGM Notice of Meeting
<b>No. of securities held after change</b>	Mr Scott Philip Kirkland 3,854,155 ordinary shares (EMV) 500,000 unlisted options, exercise price \$2.25, expiry date 31 Dec 2025  KIRKLAND CAPITAL PTY LTD <THRILL FURKHAND A/C> 415,000 total ordinary shares (EMV)
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of unlisted options following approval at Annual General Meeting.

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.